The impact of palliative irradiation on the management of patients with acquired immune deficiency syndrome.

Nobler, Myron P.; Leddy, Mary Ellen; Huh, Sun H.

doi:10.1200/jco.1987.5.1.107

Cited by 60 publications

(13 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Death resulted from opportunistic infection in all but one patient whose NHL CNS recurred. Nobler [46] confirmed the efficacy of irradiation in a study of five patients.…”

Section: Radiationsupporting

confidence: 49%

The therapy of primary brain lymphoma

Hochberg

Loeffler²,

Prados

1991

J Neuro-Oncol

View full text Add to dashboard Cite

Recommendations regarding the current therapy of primary brain lymphoma (NHL-CNS) take into account the occurrence of this tumor in immunocompetent and immunosuppressed hosts. Immunohistochemical evaluation of biopsy material or spinal fluid provides the diagnosis in 90% of patients. For the immunocompetent, pre-irradiation intra-venous or intra-arterial chemotherapy with Methotrexate alone or in combination with other agents is provided to treat tumor within multiple brain sites. Subarachnoid deposits are treated with Methotrexate by intrathecal administration. Radiation is provided after chemotherapy and for the treatment of vitreal/retinal deposits or symptomatic lesions within the spinal axis. The therapy of recurrent NHL-CNS makes use of intravenous Methotrexate or high dose Cytosine Arabinoside. Immunosuppressed patients respond to reduction of immunosuppressive medication. The therapy of NHL-CNS in the AIDS patient makes use of corticosteroids followed by cranial irradiation. A discussion of emerging trends in the therapy of NHL-CNS in the AIDS and non-AIDS population is provided.

show abstract

“…Death resulted from opportunistic infection in all but one patient whose NHL CNS recurred. Nobler [46] confirmed the efficacy of irradiation in a study of five patients.…”

Section: Radiationsupporting

confidence: 49%

The therapy of primary brain lymphoma

Hochberg

Loeffler²,

Prados

1991

J Neuro-Oncol

View full text Add to dashboard Cite

show abstract

“…As a result of the ensuing obvious cosmetic deformity, treatment is frequently sought, despite reassurances of the cysts' benign nature. Traditionally, available therapy has been limited to either repeated percutaneous aspirations, 4–6 surgical excision including enucleation or superficial parotidectomy, 1,4,7,8 radiation therapy, 6,9 and rarely, medical therapy with zidovudine (AZT) 6,7 . However, none of these treatment modalities have been able to consistently control the cysts with reasonable degrees of morbidity.…”

Section: Introductionmentioning

confidence: 99%

Doxycycline sclerosis of benign lymphoepithelial cysts in patients infected with HIV

et al. 1998

View full text Add to dashboard Cite

Benign lymphoepithelial cysts (BLCs) are a widely recognized cause of parotid gland swelling in HIV-infected patients. Although they are neither invasive nor associated with malignant degeneration, BLCs can become large and disfiguring. Multiple modalities have been used to control these cysts, but no ideal treatment has been identified. The current study examines the efficacy of doxycycline as a BLC sclerosant in eight patients, and nine BLCs (bilateral BLC in one patient). Follow-up ranged from 12 to 17 months in all cases. Doxycycline sclerosis controlled further cyst growth in 100% of cases with no serious complications. The BLCs became negligible or unnoticeable in two patients, and in six patients (seven BLCs) the cyst became fibrosed and showed no evidence of further growth over the follow-up period. Although further studies are needed to determine the long-term efficacy of this treatment modality, doxycycline sclerosis appears to offer a simple, safe, cost-effective, office-based therapeutic option for the treatment of BLCs in patients infected with HIV.

show abstract

“…AIDS-KS is known to be responsive to HAART, and control of HIV load is the primary goal in the treatment of AIDS-KS [46]. Pain, edema and cosmetic concerns arising even from slowly progressive disease can be addressed with local therapies, such as irradiation [47,48] or excision, alitretinoin gel (a retinoid approved for topical application) [49], IFN-α [50], or experimental therapies [51], such as novel angiogenesis inhibitors (reviewed in [46,[52][53][54]). Advanced or quickly progressing disease can be treated with systemic cytotoxic chemotherapy.…”

Section: Kaposi's Sarcoma Therapymentioning

confidence: 98%

Functional Genomics and the Development of Pathogenesis-Targeted Therapies for Kaposi‘s Sarcoma

2005

View full text Add to dashboard Cite

Kaposi's sarcoma (KS) is a multifocal angioproliferative disorder affecting the skin, mucosa and viscera of individuals infected with human herpesvirus-8 (HHV-8; also Kaposi's sarcoma-associated herpesvirus [KSHV]). KS is the most common neoplasm in AIDS patients; the clinical outcome of AIDS-KS is significantly improved by highly active antiretroviral therapy (HAART). However, in Africa, where the severest manifestations of KS occur, there is limited access to these and other effective but expensive drugs. Here we present a review of current efforts to identify novel therapeutic targets for the treatment of KS using functional genomics, with recommendations regarding the development of economically feasible treatments for use in Africa.

show abstract

The impact of palliative irradiation on the management of patients with acquired immune deficiency syndrome.

Cited by 60 publications

References 7 publications

The therapy of primary brain lymphoma

The therapy of primary brain lymphoma

Doxycycline sclerosis of benign lymphoepithelial cysts in patients infected with HIV

Functional Genomics and the Development of Pathogenesis-Targeted Therapies for Kaposi‘s Sarcoma

Contact Info

Product

Resources

About